In an initial report of patients with heavily pre-treated metastatic, HER2-expressing colorectal cancer, preliminary efficacy was observed with trastuzumab deruxtecan, particularly in patients with the highest degree of HER2-positivity.
Prof. Salvatore Siena (University of Milan Niguarda Cancer Center, Italy) presented results from the DESTINY-CR101 study, which stratified 3 cohorts of patients . Cohort A had HER2-overexpressing patients who had scores of 3 or higher according to immunohistochemistry testing (IHC 3 plus), as well as a score above 2 by *in situ* hybridisation (ISH). Cohort B were patients whose tumours were IHC 2 and above but were ISH-negative; cohort C were patients whose tumours were IHC >1. All patients (n=90) enrolled in the trial had tumours that were *RAS/BRAF*-wildtype and expressed HER2. A single patient had an *NRAS* mutation. All had received at least two prior line...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« ES-SCLC: pembrolizumab KEYNOTE-604 data Next Article
Tiragolumab and atezolizumab: ORR in NSCLC »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.